BRAF and non-small cell lung carcinoma: In in vitro and in in vivo preclinical NSCLC models, GSI can increase paclitaxel sensitivity, particularly in KRAS-wild-type NSCLC, suggesting that KRAS/BRAF mutation status may predict combined efficacy of GSI with paclitaxel (100).